Unilever licences Arzeda Inc.s enzyme technology
As part of its ‘Clean Future’ strategy, Unilever NV has licensed enzyme technology from Arzeda Inc. to help rid detergent production of fossil carbon.
Author Archive for: TG
About Thomas Gabrielczyk
This author has not written his bio yet.
But we are proud to say that Thomas Gabrielczyk contributed 1190 entries already.
Entries by Thomas Gabrielczyk
Bio-Me raises NOK10m
/in News/by Thomas GabrielczykOslo-based microbiome expert Bio-Me A/S has raised NOK10m in a new funding round.
Novalis Biotech closes biotech fund at 25m
/in News/by Thomas GabrielczykEarly-stage venture capital investor Novalis Biotech has closed its Biotech Acceleration Fund at 25m to drive growth of translational medicine start-ups.
Cellink AB to take-over Discover Echo Inc
/in News/by Thomas GabrielczykSwedish Cellink AB has announced a bid of $110m to take over all shares of Discover Echo Inc., 11% of which to be paid in newly issued shares.
Rheincell set to be acquired by Catalent
/in News/by Thomas GabrielczykMajor CDMO Catalent has swallowed German RheinCell Therapeutics GmbH, an iPSC specialist, to expand its offerings in cell and gene therapies.
Data protection rules may block medical progress
/in News/by Thomas GabrielczykIn an effort to ban AI tools for facial recognition, the EU risks to block European medical geneticists to recognise genetic diseases.
NeuVasQ Biotechnologies bags 20m in Series A financing
/in News/by Thomas GabrielczykNeuVasQ Biotechnologies has raised 20m through a Series A investment to advance its technology platform that restores the integrity of the blood-brain barrier in acute neurological disorders.
Coriolis Pharma expands its ATMP development facilities
/in News/by Thomas GabrielczykCoriolis Pharma will launch operations at its currently expanded ATMP development facilities by Q4/2021.
BioverSys AG bags $15m CARB-X funding
/in News/by Thomas GabrielczykCARB-X is funding Swiss pharma company BioVersys with $15.2m to develop a new class of antibiotics to treat infections caused by multidrug-resistant pathogens.
Lonza expands EU production capacity for Moderna vaccine
/in News/by Thomas GabrielczykLonza will expand its production capacity of Modernas mRNA vaccine mRNA1273 at its manufacturing site in Geelen, the Netherlands.